We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Complete Response to J&J Slows Risperdal Consta Approval
FDA Complete Response to J&J Slows Risperdal Consta Approval
February 13, 2009
The FDA issued a complete response letter to Johnson & Johnson (J&J) on its long-acting injectable antipsychotic Risperdal Consta for the adjunctive maintenance treatment of patients with frequent relapses of bipolar disorder.